Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction

(2020) Javed Butler et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

(2020) Milton Packer et al.   CIRCULATION

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

(2019) Milton Packer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

(2019) Michael E. Nassif et al.   CIRCULATION

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

(2019) Mikhail N. Kosiborod et al.   CIRCULATION

Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction

(2017) Yashashwi Pokharel et al.   JAMA Cardiology

Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire

(2015) John A. Spertus et al.  

Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire

(2015) John A. Spertus et al.   Circulation-Cardiovascular Quality and Outcomes

Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study

(2011) Inger Ekman et al.   EUROPEAN HEART JOURNAL